Skip to main content
    I

    Icecure Medical (ICCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.76
    +0.03 (+4.12%)

    Market Cap: $3.39M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Icecure Medical (ICCM) Earnings: Report Dates and Results

    Updated Aug 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Icecure Medical (ICCM) is confirmed to report earnings on Nov 18, 2026, before the open. In the quarter ended Jun 30, 2026, Icecure Medical reported EPS of -$3.11, below the -$1.37 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    39%(7/18)
    Avg Surprise
    -7.40%

    Upcoming Estimates

    Reports Nov 18, 2026 before openPeriod ending Sep 30, 2026
    EPS Consensus-$0.83
    Range-$0.83 - -$0.83
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.88+5.7%
    60d ago-$0.88+5.7%
    30d ago-$0.830.0%
    7d ago-$0.830.0%
    Current-$0.83
    Revenue Consensus
    $876.50K
    Range$850.00K - $903.00K
    2 analysts
    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.17
    Range-$1.42 - -$0.88
    5 analysts
    Revenue Consensus
    $1.63M
    Range$1.47M - $1.78M
    5 analysts

    Next Report

    ICCM has a confirmed report date of Nov 18, 2026, before the open.

    ICCM Earnings Call

    The latest ICCM earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 18 quarters below that had an estimate, ICCM beat 7, missed 8 and matched 3. Revenue for the quarter ended Jun 30, 2026 was $907000, up 72.8% from $525000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$3.11-$1.37-$1.80 - -$0.95-127.01%MissN/A20 up, 1 downAug 12, 2026$907000
    Mar 31, 2026-$0.06-$0.05-$0.05 - -$0.03-16.20%MissN/A21 up, 0 downMay 12, 2026$911000
    Dec 31, 2025-$1.80-$1.20-$1.20 - -$1.20-50.00%MissN/A11 up, 0 downMar 17, 2026$1.28M
    Sep 30, 2025-$1.80-$1.65-$1.80 - -$1.50-9.09%MissN/A22 up, 0 downNov 19, 2025$850000
    Jun 30, 2025-$1.80-$1.95-$2.10 - -$1.80+7.69%BeatN/A20 up, 1 downAug 13, 2025$525000
    Mar 31, 2025-$1.80-$2.40-$2.40 - -$2.40+25.00%BeatN/A20 up, 1 downMay 28, 2025$725000
    Dec 31, 2024-$0.08-$0.08N/A0.00%In lineN/A11 up, 0 downMar 27, 2025$875000
    Sep 30, 2024-$2.40-$2.25-$2.40 - -$2.10-6.67%MissN/A20 up, 1 downNov 26, 2024$662000
    Jun 30, 2024-$1.80-$2.10-$2.10 - -$2.10+14.29%BeatN/A20 up, 0 downAug 20, 2024$1.01M
    Mar 31, 2024-$2.40-$2.40-$2.40 - -$2.400.00%In lineN/A20 up, 0 downApr 3, 2024$743000
    Dec 31, 2023-$0.06-$0.08-$0.08 - -$0.06+21.77%BeatN/A30 up, 0 downFeb 20, 2024$1.25M
    Sep 30, 2023-$2.61-$2.70-$2.70 - -$2.70+3.33%BeatN/A30 up, 0 downNov 15, 2023$327000
    Jun 30, 2023-$2.64-$2.60-$2.70 - -$2.40-1.54%MissN/A30 up, 0 downAug 14, 2023$937000
    Mar 31, 2023-$2.40-$2.80-$3.00 - -$2.70+14.29%Beat-2100.0%30 up, 0 downMay 22, 2023$710000
    Dec 31, 2022-$0.11-$0.10-$0.11 - -$0.09-10.00%MissN/A30 up, 0 downMar 29, 2023$939000
    Sep 30, 2022-$3.30-$3.45-$3.60 - -$3.30+4.35%BeatN/A20 up, 0 downDec 5, 2022$634000
    Jun 30, 2022-$3.72-$3.60N/A-3.33%MissN/AN/AN/AAug 15, 2022$765000
    Mar 31, 2022$0.12$0.12N/A0.00%In lineN/AN/AN/AApr 1, 2022$747000
    Jun 30, 2021-$0.09N/AN/AN/AN/AN/AN/AN/ASep 23, 2021$637000
    Mar 31, 2021-$0.08N/AN/AN/AN/AN/AN/AN/AApr 12, 2021$1.44M
    Dec 31, 2020-$0.08N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$1.38M
    Sep 30, 2020-$0.07N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$635000
    Jun 30, 2020-$0.09N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$927500
    Mar 31, 2020-$0.05N/AN/AN/AN/AN/AN/AN/AJun 30, 2020$927500
    Dec 31, 2019-$0.05N/AN/AN/AN/AN/AN/AN/AMar 30, 2020$539194
    Sep 30, 2019-$0.08N/AN/AN/AN/AN/AN/AN/ADec 31, 2019$535642
    Jun 30, 2019-$0.08N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$282439
    Mar 31, 2019-$0.09N/AN/AN/AN/AN/AN/AN/AJun 30, 2019$277479
    Dec 31, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AMar 30, 2019$332121
    Sep 30, 2018-$0.08N/AN/AN/AN/AN/AN/AN/ADec 31, 2018$285093
    Mar 31, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AJun 30, 2018$251747
    Dec 31, 2017-$0.09N/AN/AN/AN/AN/AN/AN/AMar 30, 2018$58340
    Sep 30, 2017-$0.11N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$171414
    Jun 30, 2017-$0.12N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$227474
    Mar 31, 2017-$0.11N/AN/AN/AN/AN/AN/AN/AJun 30, 2017$219083
    Dec 31, 2016-$3.81N/AN/AN/AN/AN/AN/AN/AMar 30, 2017$90421
    Sep 30, 2016-$0.12N/AN/AN/AN/AN/AN/AN/ADec 31, 2016$203086
    Jun 30, 2016-$0.13N/AN/AN/AN/AN/AN/AN/ASep 30, 2016$162550
    Mar 31, 2016-$0.19N/AN/AN/AN/AN/AN/AN/AJun 29, 2016$178215
    Dec 31, 2015-$0.34N/AN/AN/AN/AN/AN/AN/AMar 30, 2016$245435
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$7.20, after -$6.68 the year before. It was -$1.09 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$7.20N/A
    Dec 31, 2024-$6.68N/A
    Dec 31, 2023-$7.71N/A
    Dec 31, 2022-$7.18N/A
    Dec 31, 2020-$0.29N/A
    Dec 31, 2019-$0.30N/A
    Dec 31, 2018-$0.26N/A
    Dec 31, 2017-$0.43N/A
    Dec 31, 2016-$4.25N/A
    Dec 31, 2015-$1.09N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,600 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,6377
    2026Q1Mar 31, 20263,4097
    2025Q4Dec 31, 20253,3976
    2025Q3Sep 30, 20252,5095
    2025Q2Jun 30, 20253,4117
    2025Q1Mar 31, 20252,9117
    2024Q2Jun 30, 20242,9937

    2026Q2 Earnings Call

    Opening remarks

    Eyal Shamir CEO Thank you, operator, and thank you, everyone, for joining us today. The first half of 2026 marks an important inflection point for IceCure. Over the past several years, we have focused on building the clinical, regulatory and scientific foundation for ProSense. We invested in generating clinical evidence, achieving important regulatory milestones and educating physicians around the world. Today, we are beginning to see those investments translate into measurable commercial momentum while continuing to generate the evidence that supports future growth. We believe what makes this stage of our evolution particularly important is that our clinical and commercial strategies are no longer progressing on separate tracks. They are increasingly reinforcing one another. Growing physician adoption generates additional real-world clinical experience, yet expands both the breadth of evidence to answer physician confidence, support future reimbursement initiatives and encourage broader adoption. As more physicians adopt ProSense, they generate additional real-world evidence creating a self-reinforcing cycle that we believe will continue to strengthen over time. This is exactly the transition we have been working towards. During the first half of the year, revenue increased approximately 45% year over year to $1.8 million, driven by growth of both ProSense systems and disposable products. More importantly, this growth reflects increasing physician adoption and utilization of our technology across our commercial installed base. One of the most meaningful metrics of commercial progress is not simply the number of systems placed, but how frequently those systems are being used. Increasing disposable probe utilization suggests that physicians are incorporating ProSense into routine clinical practice and treating more patients over time. This recurring utilization gives us confidence that commercial adoption is becoming broader, deeper and increasingly sustainable. Following FDA clearance for early-stage, low-risk breast cancer, we continue expanding our U.S. commercial footprint, achieving approximately 70% growth in our active U.S. commercial installed base. At the same time, we are strengthening our commercial organization through additional sales hires in key U.S. regions while continuing to expand our presence across select international markets. Another important example of how our clinical and commercial strategies are coming together is our FDA-approved CHOICE post-market study. I would like to emphasize an important point regarding the CHOICE study. Unlike traditional pre-market clinical studies, the CHOICE trial is a post-market study and is not separate from our commercialization strategy. Rather it is an extension of it. Participating clinical sites purchase disposable probes as part of routine patient care while simultaneously contributing valuable real-world clinical evidence. Some participating physicians have already transitioned from clinical investigators into active commercial users of ProSense, while additional leading institutions are joining the study and becoming new users of our technology.

    Frequently Asked Questions About ICCM

    When is Icecure Medical's next earnings date?

    Icecure Medical's next earnings report is confirmed for Nov 18, 2026, before the open.

    Did ICCM beat earnings estimates last quarter?

    No. Icecure Medical reported EPS of -$3.11 for the quarter ended Jun 30, 2026, below the -$1.37 estimate by 127.01%.

    What EPS do analysts expect from ICCM next quarter?

    The consensus EPS estimate for Icecure Medical for the quarter ended Sep 30, 2026 is -$0.83 from 1 analyst, with estimates from -$0.83 to -$0.83.

    How often does ICCM beat earnings estimates?

    Icecure Medical beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -22.03%.

    Does ICCM report before or after the market opens?

    Icecure Medical is confirmed to report on Nov 18, 2026, before the market opens.